文献速递淋巴瘤

诱导治疗结束时正电子发射断层扫描完全缓解(PET-CR)作为初治滤泡性淋巴瘤无进展生存期的替代终点

End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
PubMed 文献 · Br J Haematol · 2022-05-02

该研究基于5项随机试验的1505例初治滤泡性淋巴瘤患者个体数据,评估诱导结束时FDG-PET完全缓解(EoI-PET-CR)作为无进展生存期(PFS)替代终点的可行性。虽然EoI-PET-CR在预后层面可强预测PFS,但试验层面线性回归R²=0.56(CI:0.20-0.88)、Copula模型R²=0.35(CI:0.0-0.82),未显示强相关性。作者认为估计不确定性高可能与试验数少及有PET数据的人群有关,维持治疗可能扭曲关联,仍需 refined 评估。

要点

  • EoI-PET-CR在预后层面可强预测PFS,但试验层面替代性未达强相关。
  • 试验层面线性回归R²=0.56(CI:0.20-0.88),Copula模型R²=0.35(CI:0.0-0.82)。
  • 估计不确定性高可能与试验数量少及有PET数据的人群有关。

核心结论

  • EoI-PET-CR在预后层面可强预测PFS,但试验层面评估未显示强相关性, refined 评估基于PET-CR的替代终点仍被需要。

研究设计与样本

  • 基于5项随机试验的1505例初治滤泡性淋巴瘤患者个体数据,评估诱导结束时FDG-PET完全缓解(EoI-PET-CR)作为PFS替代终点的可行性。
  • 采用线性回归(RWLS²)和双变量Copula(RCopula²)模型进行试验层面替代性分析。

主要发现

  • EoI-PET-CR在预后层面可强预测PFS。
  • 试验层面线性回归RWLS²=0.56(CI:0.20-0.88),Copula模型RCopula²=0.35(CI:0.0-0.82)。
  • 估计不确定性高可能与试验数量少及有PET数据的人群有关。
  • 维持治疗影响诱导后的PFS但不影响EoI-PET-CR终点,可能扭曲治疗效应之间的关联。

关键数值与推荐

  • 试验层面替代性线性回归RWLS²=0.56(CI:0.20-0.88)。
  • 试验层面替代性双变量Copula模型RCopula²=0.35(CI:0.0-0.82)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 估计不确定性高,可能与试验数量少及有PET数据的人群有关。
  • 维持治疗影响PFS但不影响EoI-PET-CR终点,可能扭曲治疗效应之间的关联。
  • refined 评估基于PET-CR的替代终点仍被需要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Progression-free survival (PFS) has been the regulatory primary end-point for recent phase III trials in first-line follicular lymphoma (FL), but requires prolonged follow-up. Complete response (CR) at 30 months after initiation of induction treatment was validated as surrogate end-point for PFS. Our objective was to further evaluate surrogacy of CR measured by [18 F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at the end of induction (EoI). Individual patient data were analysed from 1505 patients from five randomized trials. Trial-level surrogacy examining the association between treatment effects on EoI-PET-CR and PFS was evaluated using linear regression ( RWLS2 ) and bivariate Copula ( RCopula2 ) models. Although EoI-PET-CR strongly predicted PFS at a prognostic level, the trial-level assessment did not show strong correlation ( RWLS2=0.56 , confidence interval [CI]: 0.20-0.88; RCopula2=0.35 , CI: 0.0-0.82). The high uncertainty in estimation was possibly due to the small number of trials and the population of patients with available PET data. Maintenance therapy affecting PFS beyond induction treatment, but not EoI-PET-CR end-point, may have distorted the association between treatment effects. However, there will probably be a number of additional trials approaching completion with available PET response data. Refined evaluation of PET-CR based surrogate end-points is still warranted.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dixon JG, Dimier N, Nielsen T, et al. End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma. Br J Haematol. 2022. PMID: 35491747. doi:10.1111/bjh.18217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。